| Similar Articles |
|---|
 |
The Motley Fool
October 31, 2011
Tim Beyers |
Auxilium Pharmaceuticals Shares Plunged: What You Need to Know Shares of Auxilium Pharmaceuticals fell more than 13% in early trading after the company revealed lower demand for procedures relating to the hand disorder known as Dupuytren's contracture.   |
The Motley Fool
October 12, 2010
Travis Hoium |
King Pharmaceuticals Shares Popped: What You Need to Know King Pharmaceuticals shares are up nearly 40% today after it was announced the company would be purchased by Pfizer Inc. |
The Motley Fool
December 18, 2008
Brian Orelli |
Pfizer Needs Bigger Deals Buy something significant already! |
The Motley Fool
July 25, 2011
Seth Jayson |
Why the Future Looks Bright for Auxilium Pharmaceuticals Although Auxilium Pharmaceuticals shows inventory growth that outpaces revenue growth, the company may also display positive inventory divergence, suggesting management sees increased demand. |
BusinessWeek
October 29, 2009
Arlene Weintraub |
Testosterone Is Sure Looking Virile Despite legal setbacks and FDA delays, youth-crazed boomers are making testosterone a billion-dollar industry. |
Chemistry World
May 26, 2015
Phillip Broadwith |
Endo to buy Par as generics consolidation continues Irish-headquartered firm Endo Pharmaceuticals has agreed to buy private US firm Par Pharmaceuticals in a deal worth around $8 billion in a combination of cash, shares and assumed debt. |
Chemistry World
October 10, 2014
Phillip Broadwith |
Endo outbids QLT for Auxilium merger US biotech Auxilium has backed out of a merger with Canadian firm QLT, in favor of a deal with US-based Endo. |
The Motley Fool
December 30, 2010
Brian Orelli |
That's What You Call Product Differentiation? Endo Pharma misses the mark with its treatment for low testosterone, which the Food and Drug Administration approved yesterday. |
